CN110981945B - Expression preparation and application of porcine circovirus type 2 recombinant Cap protein - Google Patents
Expression preparation and application of porcine circovirus type 2 recombinant Cap protein Download PDFInfo
- Publication number
- CN110981945B CN110981945B CN201911246097.3A CN201911246097A CN110981945B CN 110981945 B CN110981945 B CN 110981945B CN 201911246097 A CN201911246097 A CN 201911246097A CN 110981945 B CN110981945 B CN 110981945B
- Authority
- CN
- China
- Prior art keywords
- recombinant
- circovirus type
- porcine circovirus
- protein
- cap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 114
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 98
- 241001673669 Porcine circovirus 2 Species 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000014509 gene expression Effects 0.000 title abstract description 18
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 41
- 241000894006 Bacteria Species 0.000 claims abstract description 21
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 14
- 210000002845 virion Anatomy 0.000 claims abstract description 13
- 241000588724 Escherichia coli Species 0.000 claims abstract description 10
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims abstract description 8
- 230000001939 inductive effect Effects 0.000 claims abstract description 7
- 230000001131 transforming effect Effects 0.000 claims abstract description 6
- 229960005486 vaccine Drugs 0.000 claims description 17
- 241000700605 Viruses Species 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 5
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 1
- 238000004153 renaturation Methods 0.000 abstract description 21
- 238000000034 method Methods 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000000746 purification Methods 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 78
- 230000003053 immunization Effects 0.000 description 44
- 238000002649 immunization Methods 0.000 description 38
- 239000000243 solution Substances 0.000 description 37
- 241001533384 Circovirus Species 0.000 description 33
- 229940031626 subunit vaccine Drugs 0.000 description 31
- 108010001267 Protein Subunits Proteins 0.000 description 26
- 102000002067 Protein Subunits Human genes 0.000 description 26
- 238000001514 detection method Methods 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241000202347 Porcine circovirus Species 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 101150044789 Cap gene Proteins 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000007790 scraping Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 210000004237 neck muscle Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000009210 therapy by ultrasound Methods 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 230000006996 mental state Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 229940023143 protein vaccine Drugs 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 2
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 2
- 102100024407 Jouberin Human genes 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 2
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010068265 aspartyltyrosine Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- CVKOQHYVDVYJSI-QTKMDUPCSA-N Arg-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCN=C(N)N)N)O CVKOQHYVDVYJSI-QTKMDUPCSA-N 0.000 description 1
- HJDNZFIYILEIKR-OSUNSFLBSA-N Arg-Ile-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HJDNZFIYILEIKR-OSUNSFLBSA-N 0.000 description 1
- GMFAGHNRXPSSJS-SRVKXCTJSA-N Arg-Leu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GMFAGHNRXPSSJS-SRVKXCTJSA-N 0.000 description 1
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 1
- PAPSMOYMQDWIOR-AVGNSLFASA-N Arg-Lys-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PAPSMOYMQDWIOR-AVGNSLFASA-N 0.000 description 1
- YNSUUAOAFCVINY-OSUNSFLBSA-N Arg-Thr-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YNSUUAOAFCVINY-OSUNSFLBSA-N 0.000 description 1
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 1
- JZRLLSOWDYUKOK-SRVKXCTJSA-N Asn-Asp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N JZRLLSOWDYUKOK-SRVKXCTJSA-N 0.000 description 1
- PBSQFBAJKPLRJY-BYULHYEWSA-N Asn-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N PBSQFBAJKPLRJY-BYULHYEWSA-N 0.000 description 1
- JZLFYAAGGYMRIK-BYULHYEWSA-N Asn-Val-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O JZLFYAAGGYMRIK-BYULHYEWSA-N 0.000 description 1
- BKXPJCBEHWFSTF-ACZMJKKPSA-N Asp-Gln-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O BKXPJCBEHWFSTF-ACZMJKKPSA-N 0.000 description 1
- WDMNFNXKGSLIOB-GUBZILKMSA-N Asp-Met-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)O)N WDMNFNXKGSLIOB-GUBZILKMSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- QDXMSSWCEVYOLZ-SZMVWBNQSA-N Gln-Leu-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCC(=O)N)N QDXMSSWCEVYOLZ-SZMVWBNQSA-N 0.000 description 1
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 1
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- FHKZHRMERJUXRJ-DCAQKATOSA-N His-Ser-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 FHKZHRMERJUXRJ-DCAQKATOSA-N 0.000 description 1
- CGAMSLMBYJHMDY-ONGXEEELSA-N His-Val-Gly Chemical compound CC(C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N CGAMSLMBYJHMDY-ONGXEEELSA-N 0.000 description 1
- NAFIFZNBSPWYOO-RWRJDSDZSA-N Ile-Thr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N NAFIFZNBSPWYOO-RWRJDSDZSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 1
- YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 1
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 1
- YEIYAQQKADPIBJ-GARJFASQSA-N Lys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O YEIYAQQKADPIBJ-GARJFASQSA-N 0.000 description 1
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 208000005119 Necrotizing Pneumonia Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 1
- KIEPQOIQHFKQLK-PCBIJLKTSA-N Phe-Asn-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KIEPQOIQHFKQLK-PCBIJLKTSA-N 0.000 description 1
- MECSIDWUTYRHRJ-KKUMJFAQSA-N Phe-Asn-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O MECSIDWUTYRHRJ-KKUMJFAQSA-N 0.000 description 1
- HTKNPQZCMLBOTQ-XVSYOHENSA-N Phe-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N)O HTKNPQZCMLBOTQ-XVSYOHENSA-N 0.000 description 1
- FMMIYCMOVGXZIP-AVGNSLFASA-N Phe-Glu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O FMMIYCMOVGXZIP-AVGNSLFASA-N 0.000 description 1
- UAMFZRNCIFFMLE-FHWLQOOXSA-N Phe-Glu-Tyr Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N UAMFZRNCIFFMLE-FHWLQOOXSA-N 0.000 description 1
- XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 1
- 101100382437 Porcine circovirus 2 Cap gene Proteins 0.000 description 1
- WWAQEUOYCYMGHB-FXQIFTODSA-N Pro-Asn-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 WWAQEUOYCYMGHB-FXQIFTODSA-N 0.000 description 1
- RUDOLGWDSKQQFF-DCAQKATOSA-N Pro-Leu-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O RUDOLGWDSKQQFF-DCAQKATOSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- DKKGAAJTDKHWOD-BIIVOSGPSA-N Ser-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)C(=O)O DKKGAAJTDKHWOD-BIIVOSGPSA-N 0.000 description 1
- MQQBBLVOUUJKLH-HJPIBITLSA-N Ser-Ile-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MQQBBLVOUUJKLH-HJPIBITLSA-N 0.000 description 1
- GZGFSPWOMUKKCV-NAKRPEOUSA-N Ser-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO GZGFSPWOMUKKCV-NAKRPEOUSA-N 0.000 description 1
- GCXFWAZRHBRYEM-NUMRIWBASA-N Thr-Gln-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O GCXFWAZRHBRYEM-NUMRIWBASA-N 0.000 description 1
- CRZNCABIJLRFKZ-IUKAMOBKSA-N Thr-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N CRZNCABIJLRFKZ-IUKAMOBKSA-N 0.000 description 1
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 1
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 1
- XGFYGMKZKFRGAI-RCWTZXSCSA-N Thr-Val-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N XGFYGMKZKFRGAI-RCWTZXSCSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XZSJDSBPEJBEFZ-QRTARXTBSA-N Trp-Asn-Val Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O XZSJDSBPEJBEFZ-QRTARXTBSA-N 0.000 description 1
- KXIQQAWIPDDVOE-BPUTZDHNSA-N Trp-Pro-Cys Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O KXIQQAWIPDDVOE-BPUTZDHNSA-N 0.000 description 1
- KDGFPPHLXCEQRN-STECZYCISA-N Tyr-Arg-Ile Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KDGFPPHLXCEQRN-STECZYCISA-N 0.000 description 1
- MTEQZJFSEMXXRK-CFMVVWHZSA-N Tyr-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N MTEQZJFSEMXXRK-CFMVVWHZSA-N 0.000 description 1
- NRFTYDWKWGJLAR-MELADBBJSA-N Tyr-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O NRFTYDWKWGJLAR-MELADBBJSA-N 0.000 description 1
- FDKDGFGTHGJKNV-FHWLQOOXSA-N Tyr-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FDKDGFGTHGJKNV-FHWLQOOXSA-N 0.000 description 1
- VBFVQTPETKJCQW-RPTUDFQQSA-N Tyr-Phe-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VBFVQTPETKJCQW-RPTUDFQQSA-N 0.000 description 1
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 1
- AEOFMCAKYIQQFY-YDHLFZDLSA-N Tyr-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AEOFMCAKYIQQFY-YDHLFZDLSA-N 0.000 description 1
- KLOZTPOXVVRVAQ-DZKIICNBSA-N Tyr-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KLOZTPOXVVRVAQ-DZKIICNBSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10051—Methods of production or purification of viral material
- C12N2750/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses an expression preparation and application of porcine circovirus type 2 recombinant Cap protein. The sequence of the porcine circovirus type 2 recombinant Cap protein is the sequence 2 in the sequence table. The coding gene is sequence 1 in the sequence table. The preparation method of the porcine circovirus type 2 Cap recombinant protein virion comprises the following steps: 1) the recombinant vector for expressing the porcine circovirus type 2 Cap recombinant protein is used for transforming the competence of escherichia coli BL21(DE3) to obtain recombinant bacteria for expressing porcine circovirus type 2 Cap recombinant protein virions; 2) inducing expression of the recombinant bacteria, collecting and crushing the bacteria, and collecting inclusion bodies; 3) and (4) carrying out dissolution and renaturation on the inclusion body to obtain the assembled porcine circovirus type 2 Cap recombinant protein virion. The invention adopts an escherichia coli expression system to express the porcine circovirus type 2 Cap protein, has large protein expression quantity and simple purification method, greatly reduces the production cost and is beneficial to promoting mass production.
Description
Technical Field
The invention belongs to the technical field of biology, and relates to inclusion body expression, purification, renaturation and application of porcine circovirus type 2 recombinant Cap protein.
Background
Porcine Circovirus (PCV) belongs to the family circoviridae, the genus circovirus, with three serotypes PCV1, PCV2 and PCV 3. The PCV virion is of a regular icosahedral symmetrical structure, has the diameter of about 17nm, is the smallest animal virus known at present, and has no envelope on the surface of the virus. Porcine circovirus disease is an infectious disease caused by porcine circovirus type 2, and is clinically mainly characterized by poor growth and development, emaciation, sow dysreproduction, dyspnea, subcutaneous lymph node high swelling, hemorrhage, necrosis and the like, and is divided into clinical types such as weaned piglet multisystemic failure syndrome (PMWS), porcine dermatitis and nephrotic syndrome (PNDS), Proliferative and Necrotizing Pneumonia (PNP), Reproductive failure (Reproductive failure), Perinatal myocarditis (porcine myocarpis), piglet Congenital tremor (genetic tumors) and the like. The research shows that PCV2 can cause the apoptosis of immune cells in the porcine lymphatic system, cause the immunosuppression, lead the resistance of the organism to be reduced, thereby inducing the mixed infection and the secondary infection of a plurality of bacterial viruses and causing huge economic loss to the breeding industry.
Porcine circovirus is a single negative-strand circular DNA virus, the viral genome containing at least 11 open reading frames, i.e., ORF1-ORF 11. Wherein ORF1 is the largest open reading frame of PCV, encodes the Rep protein (314aa, about 36kDa), a virus replication-related protein responsible for the cross-reactivity of PCV1 and PCV2 antigens, ORF1 is relatively conserved, with about 85% homology between the two serotypes; ORF2 encodes the viral capsid protein Cap protein (233aa, about 27kDa), which is a type-specific antigen with good immunogenicity, no antigenic cross-reactivity between the two serotypes, and only 67% homology between the two serotypes. PCV3 is a new serous type discovered only in recent years, and the amino acid homology of the Cap protein encoded by ORF2 with the Cap protein of PCV2 is about 34%, so relatively few studies on PCV3 are carried out at present.
At present, five types of PCV2 gene subtypes reported in China are PCV2a, PCV2b, PCV2c, PCV2d and PCV2 e. Serological investigation finds that the domestic swinery positive rate is as high as 52.8-100%, the morbidity is as high as 50%, the mortality is generally 5-70% due to different conditions of pig farms, secondary infection and the like, and huge economic loss is caused to the pig industry. Vaccine immunization plays a critical role in the prophylactic control of PCV 2. At present, porcine circovirus vaccines mainly comprise inactivated vaccines, attenuated live vaccines and subunit vaccines, wherein inactivated vaccines are mostly used in China, but PCV2 virus is not easy to propagate on cells, the titer of produced virus is generally low, the immune effect is not ideal enough, and in addition, the inactivated vaccine also has the problems of difficult detection of the inactivated effect, short immune period and the like, and the production cost is increased compared with the inactivated vaccines of other viruses; the safety of subunit vaccines is accepted by the industry, but the level of the subunit vaccines produced in China is different, and the imported subunit vaccines have good immune effect but higher price.
Disclosure of Invention
The invention aims to provide a method for preparing porcine circovirus type 2 recombinant Cap protein by an Escherichia coli expression system, and the protein has good biological activity and immunogenicity.
Based on the purpose, the invention provides a porcine circovirus type 2 recombinant Cap protein, the sequence of which is sequence 2 in a sequence table.
The invention also provides a coding gene of the porcine circovirus type 2 recombinant Cap protein; preferably, the coding gene of the porcine circovirus type 2 recombinant Cap protein is shown as a sequence 2 in a sequence table.
The invention also provides a recombinant vector for expressing the porcine circovirus type 2 recombinant Cap protein, which is obtained by inserting the coding gene of the porcine circovirus type 2 recombinant Cap protein shown in the sequence 1 into an original vector.
The starting vector is preferably pET-30a (+).
The invention also aims to provide a preparation method of the porcine circovirus type 2 Cap recombinant protein virions, which comprises the following steps:
1) transforming the recombinant vector into escherichia coli BL21(DE3) competence to obtain a recombinant bacterium for expressing the porcine circovirus type 2 Cap recombinant protein virion;
2) inducing and expressing the recombinant bacteria obtained in the step 1), collecting and crushing bacteria, and collecting inclusion bodies;
3) dissolving and renaturing the inclusion body obtained in the step 2) to obtain the assembled porcine circovirus type 2 Cap recombinant protein virions.
Specifically, the method comprises the following steps:
(1) synthesizing a target gene: inserting the optimized Cap gene sequence shown in the sequence 1 between Nde I and Xho I enzyme recognition sites of pET-30a (+), obtaining a recombinant vector for expressing the recombined Cap protein, and naming the recombinant vector as pET-CapR;
(2) screening of recombinant strains: transforming the plasmid pET-CapR obtained in the step (1) into Escherichia coli competent BL21(DE 3); obtaining an engineering strain for expressing porcine circovirus type 2 Cap recombinant protein virus particles, and naming the engineering strain as E.coli-PCV 2-FJ-Cap; (3) inducing expression by inclusion bodies: culturing the strain E.coli-PCV2-FJ-Cap obtained in the step (2), and inducing expression protein by IPTG;
(4) and (3) inclusion body purification: centrifugally collecting the recombinant bacteria obtained in the step (3), ultrasonically crushing bacteria, centrifugally removing supernatant, scraping bacterial sludge on the upper layer of sediment, and collecting inclusion bodies;
(5) denaturation and renaturation of inclusion bodies: dissolving the inclusion body by using an inclusion body dissolving solution, slowly adding the dissolved inclusion body into an inclusion body renaturation solution for dilution renaturation, and stirring for 48 hours at 4 ℃; the formula of the renaturation liquid is as follows: 50mM Tris-HCl, 400mM L-arginine, pH adjusted to 8.0;
(6) concentration and purification: slowly adding the replacement solution into the renaturation solution, and concentrating at 4 ℃ to obtain concentrated Cap protein; the formula of the replacement liquid is as follows: 20mM Tris-HCl, 50mM NaCl, pH adjusted to 8.0.
The engineering strain for expressing the porcine circovirus type 2 Cap recombinant protein virions is classified and named as follows: escherichia coli, strain name E.coli-PCV 2-FJ-Cap; has been preserved in China general microbiological culture Collection center (China academy of sciences, institute of microbiology, No. 3, West Lu No.1, Beijing, Chaoyang, North-China) in 16.7.2019, and the preservation number is CGMCC No. 18235.
The invention relates to application of the porcine circovirus type 2 recombinant Cap protein or the coding gene of the porcine circovirus type 2 recombinant Cap protein of claim 2 in preparation of porcine circovirus type 2 recombinant Cap protein virions.
The application of the porcine circovirus type 2 recombinant Cap protein or the coding gene of the porcine circovirus type 2 recombinant Cap protein of claim 2 in the preparation of vaccines for preventing or treating the circovirus type 2 also belongs to the protection scope of the invention.
The invention has the following positive beneficial effects:
the invention adopts an escherichia coli expression system to express the porcine circovirus type 2 recombinant Cap protein, has large protein expression quantity and simple purification method, greatly reduces the production cost and is beneficial to promoting mass production;
the invention utilizes an escherichia coli prokaryotic expression system to express the recombinant Cap protein of PCV2 in the form of inclusion body, solves the technical problem, ensures that the recombinant Cap protein obtained after the inclusion body is processed has higher VLP assembly rate, better biological activity and immunogenicity, greatly reduces the production cost and lays a foundation for the development of subunit vaccine.
The invention optimizes the coding sequence of the porcine circular ring 2 type recombinant Cap protein, improves the protein expression amount, and treats the inclusion body by the protein renaturation liquid and the replacement liquid with specific formulas, so that the finally obtained recombinant Cap protein has better biological activity, higher VLP (VLP) assembly rate and better protein stability;
animal experiments prove that the recombinant Cap protein prepared by the invention can generate high-level antibodies when used for immunizing mice and pigs, and lays a foundation for the establishment of vaccine preparation and detection methods.
Drawings
FIG. 1 is a PCR identification picture of porcine circovirus type 2 recombinant Cap protein CGMCC No.18235 colony;
FIG. 2 is porcine circovirus type 2 recombinant Cap protein CGMCC No.18235SDS-PAGE gel staining picture and VLP assembled electron microscope picture;
FIG. 3 shows the DLS detection result of porcine circovirus type 2 recombinant Cap protein;
FIG. 4 is SDS-PAGE gel staining pictures before and after porcine circovirus type 2 recombinant Cap protein sequence optimization.
Detailed Description
The methods in the following examples are conventional methods unless otherwise specified.
Example 1 preparation of recombinant Cap protein of porcine circovirus type 2
1. Experimental Material
The primer is synthesized from Shanghai Czeri bioengineering GmbH, and Escherichia coli BL21(DE3) is competent for laboratory preservation;
a main reagent DNA plasmid small extraction kit; peptone, yeast extract were purchased from Oxoid; IPTG, L-arginine hydrochloride, Tris-HCL from Amresco; BSA protein standards were purchased from Thermo Fisher Scientific;
2. construction of porcine circovirus type 2 recombinant Cap protein expression plasmid
The sequence of the recombinant Cap gene is from PCV2 epidemic strain separated in the laboratory, the sequence of the recombinant Cap gene is analyzed and compared, the Cap protein sequence is subjected to structure prediction after 41 basic amino acids at the N end are removed, the structure is compared with the analyzed PCV2 Cap protein structure (PDB:3R0R), and CCP4 software package is used for calculating and analyzing the van der Waals force of Contacts between subbunits. Under the premise of keeping the amino acids of main antigen regions such as B folding, C folding, BC loop, C terminal and the like on the surface of virus particles unchanged, carrying out amino acid substitution on main Contacts between 3-axis subbunits and 5-axis subbunits, for example, amino acid residues of DE loop and EF loop participating in hydrophobic interaction are subjected to a plurality of rounds of structural simulation and amino acid substitution, synthesizing a target gene by Nanjing Czeityury organism Limited after codon optimization, constructing the synthesized gene in a pET-30a (+) vector (the vector is stored by the laboratory), inserting two enzyme cutting sites of NdeI and XhoI into 5 'and 3' of a recombinant Cap gene respectively, wherein the sequence of the optimized recombinant Cap gene is shown as a sequence 1 in a sequence table, and the protein sequence expressed by the optimized recombinant Cap gene is shown as a sequence 2 in the sequence table.
3. Inducible expression of porcine circovirus type 2 recombinant Cap protein
The optimized recombinant Cap gene sequence shown in sequence 1 was inserted between Nde I and Xho I enzyme recognition sites of pET-30a (+) to obtain a recombinant vector expressing the recombinant Cap protein, which was designated as pET-CapR.
Respectively transforming the expression plasmid pET-CapR into escherichia coli BL21(DE3) competence, adding 1 mu L of expression plasmid into 100 mu L of competence, after gently shaking and uniformly mixing, carrying out ice bath for 30min, carrying out heat shock in a water bath kettle at 42 ℃ for 90s, continuously carrying out ice bath for 3min, adding 800 mu L of non-resistant LB culture medium, culturing for 1h at 37 ℃ and 200rpm, centrifuging for 5min at 6000rpm, discarding 750 mu L of supernatant, carrying out heavy suspension on the thalli by using the remaining culture medium, uniformly coating the thalli on an LB plate with kanamycin resistance, and culturing at 37 ℃ overnight.
Selecting a single colony for PCR identification, and carrying out PCR amplification on a total reaction system of 25 mu l, wherein the total reaction system contains an upstream primer PCV2-F-1(CATATGAATGGCATCTTCAACACCCG, NdeI restriction site sequence underlined) 1. mu.l, and downstream primer PCV2-R-1 (N-acetyl-L-D-L-PCV)CTCGAGCTTAGGGTTAAGTGGGGG, XhoI cleavage site sequence underlined), 1. mu.l of PCR enzyme MIX 12.5. mu.l, 9.5. mu.l of sterile distilled water, and 1. mu.l of template DNA. Circulating reaction parameters: pre-denaturation at 94 ℃ for 3 min; denaturation at 94 ℃ for 45 seconds, annealing at 56 ℃ for 30 seconds, and extension at 72 ℃ for 1 minute for 32 cycles; final extension at 72 ℃ for 10 min.
The PCR products were detected by electrophoresis on a 1% agarose gel (see FIG. 1 for results). As can be seen from FIG. 1, a band of about 600bp was amplified, corresponding to the expected size of the amplified fragment.
The recombinant engineering strain with positive detection is an engineering strain for expressing porcine circovirus type 2 Cap recombinant protein virions, and is classified and named as follows: escherichia coli, strain name E.coli-PCV 2-FJ-Cap; has been preserved in China general microbiological culture Collection center (China academy of sciences, institute of microbiology, No. 3, West Lu No.1, Beijing, Chaoyang, North-China) in 16.7.2019, and the preservation number is CGMCC No. 18235.
Culturing E.coli-PCV2-FJ-Cap positive single colony overnight at the temperature of 37 ℃ at 200rpm to be used as a seed solution, inoculating the seed into LB culture medium with kana resistance according to the proportion of 1:100 the next day, culturing at the temperature of 37 ℃ at 200rpm for 2-3 h, adding IPTG with the final concentration of 1mmol/L when the OD600 of the bacterial solution reaches 0.6-0.8, and continuing to perform induction culture at the temperature of 37 ℃ for 5 h.
4. Collecting and crushing thallus
Centrifuging the thallus for 10min at 5000rpm, collecting the thallus, resuspending the thallus with PBS, concentrating the recombinant Escherichia coli by 10 times, namely centrifuging 50mL of bacterial liquid, then resuspending with 5mL of PBS, ultrasonically crushing the bacteria, and setting parameters of an ultrasonic crusher as follows: the power is 190W, the operation is 5s, the operation is stopped for 10s, the ultrasonic treatment is carried out for 10min, and the thalli are completely broken.
5. Purification of Inclusion bodies
Centrifuging the bacterium solution subjected to the ultrasonic treatment at 12000rpm for 10min at low temperature, discarding the supernatant, scraping the upper layer of gray bacterium mud by using a cell scraper, fully resuspending the inclusion body by using an inclusion body washing solution, centrifuging at 12000rpm for 10min at low temperature, discarding the supernatant, and scraping the bacterium mud again to obtain a primarily purified inclusion body;
the inclusion body washing solution has the following formula: 0.5% Triton X-100, 50mM Tris-HCl, 300mM NaCl, pH adjusted to 8.0.
6. Denaturation and renaturation of Inclusion bodies
The inclusion bodies were weighed, dissolved in a solution at a ratio of 30mg/mL, and stirred thoroughly overnight to completely dissolve the inclusion bodies. 2mL of the inclusion body solution is slowly added into 200mL of renaturation solution, the renaturation is carried out for 48h under the stirring at the temperature of 4 ℃, and the mixture is concentrated to 50mL by a concentration cup.
The inclusion body dissolving solution has the following formula: 8M Urea, 50mM Tris-HCl, 100mM NaCl, 10% glycerol, 10mM EDTA, pH adjusted to 8.0.
The formula of the renaturation liquid is as follows: 50mM Tris-HCl, 400mM L-arginine, pH adjusted to 8.0.
7. Concentration and replacement of renaturation liquid
And slowly adding the replacement solution to the renaturation solution to 1L, stirring at 4 ℃, and concentrating to 50mL to obtain the renaturated Cap protein.
The formula of the replacement liquid is as follows: 20mM Tris-HCl, 50mM NaCl, pH adjusted to 8.0.
8. Protein characterization and electron microscopy
The purity of the recombinant Cap protein was checked by SDS-PAGE and the assembly of VLPs was checked by electron microscopy (see FIG. 2 for results).
9. DSL (dynamic light scattering) detection
The assembly of the formed VLPs was detected by DSL (dynamic light scattering) and the results are shown in fig. 3, which shows that the radius of the particles was 8.87nm, accounting for more than 90% (see fig. 3).
Example 2 preparation of porcine circovirus type 2 recombinant Cap protein subunit vaccine
1. Protein production
pET-CapR was picked and transformed into Escherichia coli BL21(DE3) to obtain recombinant strain single colony E.coli-PCV2-FJ-Cap expressing recombinant Cap protein was prepared according to the method of steps 3-7 in example 1, namely: escherichia coli E.coli-coli-PCV 2-FJ-Cap CGMCC No.18235 is inoculated in 20ml of LB culture medium, the mixture is cultured overnight at 37 ℃ and 200rpm to serve as a seed solution, the seeds are inoculated in 5L of LB culture medium containing kanamycin resistance on the next day according to the proportion of 1:100, the culture is carried out for 2-3 h at 37 ℃ and 200rpm, IPTG with the final concentration of 1mmol/L is added when the OD600 of the bacterial solution reaches 0.6-0.8, and the induction culture is continued for 5h at 37 ℃. Centrifuging the thallus at 5000rpm for 10min, collecting the thallus, re-suspending the thallus by using 500mL PBS, ultrasonically crushing the thallus, and setting parameters of an ultrasonic crusher as follows: power 190W, working 5s, switching off 10s, ultrasound 1 h. Centrifuging at 12000rpm for 10min after ultrasonic treatment, removing the supernatant, scraping off gray bacterial mud, resuspending the inclusion bodies by inclusion body cleaning solution, centrifuging at 12000rpm for 10min, removing the supernatant, scraping off bacterial mud again, and obtaining the preliminarily purified inclusion bodies. The inclusion bodies were dissolved at a ratio of 30mg/mL and thoroughly stirred overnight. 2mL of the inclusion body solution is slowly added into 200mL of renaturation solution, and the renaturation is carried out for 48h under the stirring at the temperature of 4 ℃. And slowly adding the replacement solution to the renaturation solution to 1L, stirring at 4 ℃, and concentrating to 50mL to obtain the renaturated recombinant Cap protein. And finally, detecting the concentration of the recombinant Cap protein by using an SDS-PAGE gel gray scale method.
Meanwhile, the wild-type porcine circovirus type 2 Cap gene (sequence 3 in the sequence table) is inserted between Nde I and Xho I enzyme recognition sites of pET-30a (+) to obtain a recombinant vector for expressing wild Cap protein, and the recombinant vector is named as pET-Cap.
And (2) selecting a single colony of a recombinant bacterium for transforming escherichia coli BL21(DE3) into pET-Cap to obtain competence and expressing a recombinant wild Cap protein, inoculating the single colony into 20ml of LB culture medium, culturing at 37 ℃ overnight at 200rpm to obtain a seed solution, inoculating 5L of LB culture medium containing kanamycin resistance into the seeds on the next day according to the ratio of 1:100, culturing at 37 ℃ for 2-3 hours at 200rpm, adding IPTG (isopropyl-beta-thiogalactoside) with the final concentration of 1mmol/L when the OD600 of the bacterial solution reaches 0.6-0.8, and continuing to perform induction culture at 37 ℃ for 5 hours. Centrifuging the thallus at 5000rpm for 10min, collecting the thallus, re-suspending the thallus by using 500mL PBS, ultrasonically crushing the thallus, and setting parameters of an ultrasonic crusher as follows: power 190W, working 5s, switching off 10s, ultrasound 1 h. Centrifuging at 12000rpm for 10min after ultrasonic treatment, removing the supernatant, scraping off gray bacterial mud, resuspending the inclusion bodies by inclusion body cleaning solution, centrifuging at 12000rpm for 10min, removing the supernatant, scraping off bacterial mud again, and obtaining the preliminarily purified inclusion bodies. The inclusion bodies were dissolved at a ratio of 30mg/mL and thoroughly stirred overnight. 2mL of the inclusion body solution is slowly added into 200mL of renaturation solution, and the renaturation is carried out for 48h under the stirring at the temperature of 4 ℃. And slowly adding the replacement solution to the renaturation solution to 1L, stirring at 4 ℃, and concentrating to 50mL to obtain the renaturated recombinant Cap protein. And finally, detecting the concentration of the recombinant Cap protein by using an SDS-PAGE gel gray scale method.
The result shows that the coding sequence of the porcine circovirus type 2 Cap protein is optimized, the protein expression quantity is improved, the expression quantity of the Cap gene sequence in the inclusion body before and after optimization is compared by an SDS-PAGE method, the result shows that the expression quantity of the sequence-optimized Cap protein inclusion body is improved by about 35 percent (as shown in figure 4) compared with that before and after optimization, the final rate of the sequence-optimized Cap protein is about 160mg/L of culture solution after washing, denaturation and renaturation of the inclusion body, and the final rate of the Cap protein before optimization is about 50mg/L of culture solution.
Preparation of 2-circovirus type 2 recombinant Cap protein subunit vaccine
The recombinant Cap protein subjected to filtration sterilization is mixed with 206 adjuvant of SEPPIC company according to the mass ratio of 1:1 to prepare the vaccine, the final concentration of the Cap protein in the vaccine is 0, 5, 10, 20, 50 and 100 mu g/ml respectively, the emulsification condition is that the adjuvant and the water phase are respectively warm-bathed to 31 ℃, the water phase is slowly added into the adjuvant, the stirring is carried out at 350rpm for 5min, and the cold bath is carried out at 20 ℃ for 1 hour to avoid moving and stirring. And (3) after the mixing is complete, obtaining the vaccine composition, wherein the emulsification quality of the vaccine can reach the quality standard specified by the state.
Example 3: immunogenicity research of porcine circovirus type 2 recombinant Cap protein subunit vaccine
1. Piglet safety test
Screening 35 circular antigen antibody double-negative piglets with the ages of 2-3 weeks for carrying out a safety test of the circular virus type 2 recombinant Cap protein subunit vaccine. Grouping condition: randomly selecting 30 piglets to be evenly divided into 5 groups and 5 piglets per group to serve as a vaccine immunization group, immunizing 4ml of circovirus type 2 recombinant Cap protein subunit vaccine containing 5 mu g/ml recombinant Cap protein by each pig in the immunization group 1, and immunizing 4ml of circovirus type 2 recombinant Cap protein subunit vaccine containing 10 mu g/ml recombinant Cap protein by each pig in the immunization group 2; each pig of the immunization group 3 is immunized with 4ml of a circovirus type 2 recombinant Cap protein subunit vaccine containing 20 mug/ml recombinant Cap protein, each pig of the immunization group 4 is immunized with 4ml of a circovirus type 2 recombinant Cap protein subunit vaccine containing 50 mug/ml recombinant Cap protein, and each pig of the immunization group 5 is immunized with 4ml of a circovirus type 2 Cap protein subunit vaccine containing 100 mug/ml recombinant Cap protein; immunization group 6 Each pig immunized 4ml of circovirus type 2 Cap protein subunit vaccine of wild Cap protein at 100 mug/ml; the remaining 5 heads served as control groups, 4ml of PBS per head and neck muscle injection. Measuring the body temperature every 0-7 d after immunization; continuously observing the appetite and mental state of the swinery for 14 days; and observing and touching whether the local part of the injection part has the tumor or not.
After the circovirus type 2 Cap protein subunit vaccine is used for immunizing all groups of piglets, no obvious body temperature rise phenomenon occurs, and the pigs eat the vaccine normally and have good mental state; the vaccine injection site was free of pain and lumps at 5d post-immunization (table 1). The vaccine is proved to have good safety for the immunized piglets.
Table 1 shows the clinical symptom monitoring results of piglets immunized by porcine circovirus type 2 recombinant Cap protein vaccine
| Group of | Body temperature | Appetite stimulation | Mental state | Injection site | Health condition | Survival |
| Immunization group | ||||||
| 1 | Is normal | Is normal | Good effect | No abnormality | |
100 |
| Immunization group | ||||||
| 2 | Is normal | Is normal | Good effect | No abnormality | |
100 |
| Immunization group | ||||||
| 3 | Is normal | Is normal | Good effect | No abnormality | |
100％ |
| Immunization group 4 | Is normal | Is normal | Good effect | No abnormality | |
100％ |
| Immunization group 5 | Is normal | Is normal | Good effect | No abnormality | |
100％ |
| Immunization group 6 | Is normal | Is normal | Good effect | No abnormality | |
100％ |
| Control group | Is normal | Is normal | Good effect | No abnormality | |
100％ |
2. Mouse immunization test
2.1 mouse immunization procedure
35 5-6 weeks old circular antigen antibody double-negative healthy clean female BALB/c mice are subjected to an antibody level generation test of circular virus type 2 recombinant Cap protein subunit vaccine. Grouping condition: randomly selecting 30 mice to be evenly divided into 6 groups and 5 mice per group as vaccine immunization groups, wherein the immunization groups comprise 0.2ml of circovirus type 2 Cap protein subunit vaccine containing 5 mu g/ml of circovirus recombinant Cap protein under subcutaneous multipoint immunization of the back of each mouse, 0.2ml of circovirus type 2 recombinant Cap protein subunit vaccine containing 10 mu g/ml of circovirus recombinant Cap protein under subcutaneous multipoint immunization of the back of each mouse, 0.2ml of circovirus type 2 recombinant Cap protein subunit vaccine containing 20 mu g/ml of circovirus recombinant Cap protein under subcutaneous multipoint immunization of the back of each mouse, the immunization groups comprise 0.2ml of circovirus type 2 recombinant Cap protein subunit vaccine containing 50 mu g/ml of circovirus recombinant Cap protein under subcutaneous multipoint immunization of the back of each mouse, immunizing a group of mice with 0.2ml of circovirus type 2 recombinant Cap protein subunit vaccine containing 100 microgram/ml of circovirus recombinant Cap protein at multiple points in the back subcutaneous of each mouse; sixthly, performing subcutaneous multipoint immunization on the back of each mouse to obtain 0.2ml of circovirus type 2 Cap protein subunit vaccine containing 100 mu g/ml of circovirus wild Cap protein; the remaining 5 were used as control groups, each with 0.2ml of subcutaneous multi-spot immunization in PBS per back. Blood was collected 3 weeks and 5 weeks after the initial immunization, and serum was separated and measured for PCV2ELISA and neutralizing antibodies.
2.2 mouse antibody detection method
The ELISA antibody detection method is as follows: coating the circular ring Cap protein with pH9.6 carbonate buffer solution, the concentration is 1 μ g/ml, 100 μ l/hole, coating overnight at 4 ℃, adding 300 μ l of 0.5% casein blocking solution to block the plate after washing, and sealing at 37 ℃ for 2 h; diluting the serum to be detected by using a sample diluent in a multiple ratio, adding the diluted sample diluent into a coated plate, setting a negative and positive serum control group at the same time, acting for 1h at 37 ℃, and washing; adding goat anti-mouse secondary antibody (diluted 1: 10000), acting at 37 deg.C for 1h with 100 μ l/well, and washing; adding substrate color development liquid TMB for color development, 100 μ l/hole, and performing reaction at 37 deg.C for 15min, with 2M H2SO4The reaction was terminated. And (4) judging a result: the average value of the negative control OD450nm should be less than or equal to 0.15, otherwise, the negative control OD450nm is invalid; each detection value of the positive control should be between 1.0 and 2.5, otherwise, the positive control is invalid; calculation of the critical value: the cut-off value was 0.18 × the mean value of the positive control OD450nm values. The serum to be detected is determined to be positive if the OD450nm value is greater than or equal to the critical value; determination of OD450nm value in serum to be tested<The critical value is judged to be negative.
2.3 mouse antibody detection results
The results of the mouse ELISA antibodies are shown in table 2 and show: the immunization group produced ELISA antibody at 21 days, and the antibody titer further increased at 35 days, and increased with the increase of the concentration of the recombinant Cap protein, and no ELISA antibody was observed in the negative control group.
Table 2 shows the antibody detection results of porcine circovirus type 2 Cap protein CGMCC No.18235 vaccine immunized mice
3. Immunization test for piglets
3.1 piglet Immunity validation procedure
And (3) carrying out an antibody level generation test of the circular virus type 2 Cap protein subunit vaccine on 35 circular antigen antibody double-negative healthy piglets of 2-3 weeks old. Grouping condition: randomly selecting 30 piglets to be averagely divided into 5 groups and 5 piglets/group as a vaccine immunization group, wherein each piglet of the immunization group I is injected with 2ml of a circovirus type 2 Cap protein subunit vaccine containing 5 mu g/ml of circovirus type 2 Cap protein containing 5 mu g/ml of circovirus type 2 protein subunit vaccine through neck muscles, the immunization group II is injected with 2ml of a circovirus type 2 Cap protein subunit vaccine containing 10 mu g/ml of circovirus type 2 protein through neck muscles, the immunization group III is injected with 2ml of a circovirus type 2 Cap protein subunit vaccine containing 20 mu g/ml of circovirus type 2 protein containing 50 mu g/ml of circovirus type 2 protein subunit vaccine through neck muscles, the immunization group V is injected with 2ml of a circovirus type 2 Cap protein subunit vaccine containing 100 mu g/ml of circovirus type 2 protein through neck muscles, in immunization group VI, 2ml of circovirus type 2 Cap protein subunit vaccine containing 100 mu g/ml of circovirus wild Cap protein is injected into neck muscles of each piglet; and finally, selecting 5 heads as blank control groups, and avoiding immunization. Blood was collected 2 weeks, 3 weeks, and 5 weeks after the first immunization, and serum was separated and measured for PCV2ELISA antibody and neutralizing antibody.
3.2 piglet antibody detection method
3.2.1ELISA antibody detection method
Coating the circular recombinant Cap protein with a carbonate buffer solution with the pH value of 9.6, wherein the concentration is 1 mu g/ml, 100 mu l/hole, coating overnight at the temperature of 4 ℃, washing, adding 300 mu l of 0.5% casein blocking solution to seal the plate, and sealing the plate at the temperature of 37 ℃ for 2 hours; diluting the serum to be detected by using a sample diluent in a multiple ratio, adding the diluted sample diluent into a coated plate, setting a negative and positive serum control group at the same time, acting for 1h at 37 ℃, and washing; adding rabbit anti-pig secondary antibody (diluted 1: 10000), acting at 37 deg.C for 1h in 100 μ l/hole, and washing; adding substrate developing solution TMB for developing, reacting at 37 deg.C for 15min with 100 μ l/well, and treating with 2M H2SO4The reaction was terminated. And (4) judging a result: the average value of the negative control OD450nm should be less than or equal to 0.15, otherwise, the negative control OD450nm is invalid; each detection value of the positive control should be between 1.0 and 2.5, otherwise, the positive control is invalid; calculation of the critical value: the cut-off value was 0.18 × the mean value of the positive control OD450nm values. The serum to be detected is determined to be positive if the OD450nm value is greater than or equal to the critical value; determination of OD450nm value in serum to be tested<The critical value is judged to be negative.
3.2.2 detection of neutralizing antibodies
Inactivating the serum to be detected in 56 deg.C water bath for 30min, filtering, sterilizing, diluting with maintenance solution 2 times to 1:1024 times, and diluting the proliferated PCV2 with maintenance solution to 1 × 106TCID50/ml, then mixed with different gradient diluted serum in equal volume, 37 ℃ water bath for 1 h. The nutrient solution in the 96-well cell plate full of PK15 cells was discarded, and after washing with pure DMEM, the serum virus mixture was added to the wells in 3 replicates per serum dilution set at 100. mu.l/well and incubated at 37 ℃ for 72 h. Simultaneously setting positive and negative serum control and blank controlThen, the neutralizing antibody titer of the serum was measured by IFA method, and the maximum dilution of the serum inhibiting 50% PCV2 infection was used as the neutralizing antibody titer of the serum to be tested.
3.3 piglet antibody test results
3.3.1ELISA antibody detection results
The results of the ELISA antibody detection of the piglets are shown in Table 3, and the results show that the antibodies can be generated 14 days after the immunization of the piglets, the ELISA antibodies are increased along with the increase of the concentration of the Cap protein, and the antibody titer is increased along with the increase of the immune cycle.
Table 3 shows the antibody detection results of porcine circovirus type 2 recombinant Cap protein vaccine immunized piglets
3.3.2 piglet neutralizing antibody detection results
The results of the detection of the neutralizing antibody of the piglets are shown in table 4, and the results show that the neutralizing antibody can be generated 14 days after the piglets are immunized, the neutralizing antibody is increased along with the increase of the concentration of the recombinant Cap protein, and the antibody titer is increased along with the increase of the immune cycle.
Table 4 shows the detection results of neutralizing antibodies of porcine circovirus type 2 recombinant Cap protein vaccines after immunizing piglets
Sequence listing
<110> Zhongmu industries GmbH
<120> expression preparation and application of porcine circovirus type 2 Cap protein
<130> WHOI190107
<160> 3
<170> PatentIn version 3.5
<210> 1
<211> 579
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
aatggcatct tcaacacccg cctctcccgc accatcggtt atactgtcaa gaaaaccaca 60
gtcagaacgc cctcctggaa tgtggacatg atgagattta atattaatga ttttcttccc 120
ccaggagggg gctcaaaccc cctcactgtg ccctttgaat actacagaat aaggaaggtt 180
aaggttgaat tctggccctg ctccccaatc acccagaatg gtaggggagt gggctccact 240
gctgttattc tagatattaa ctttgtaaca aaggccaatg ccctaatcta tgacccctat 300
gtaaactact cctcccgcca taccataacc cagcccttct cctaccactc ccggtacttt 360
accccgaaac ctgtccttga taggacaatc gattacttcc aacccaataa caaaagaaat 420
caactctggc tgagactaca aactactgga aatgtagacc atgtaggcct cggcactgcg 480
ttcgaaaaca gtatatacga ccaggactac aatatccgta taaccatgta tgtacaattc 540
agagaattta atcttaaaga ccccccactt aaccctaag 579
<210> 2
<211> 193
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Asn Gly Ile Phe Asn Thr Arg Leu Ser Arg Thr Ile Gly Tyr Thr Val
1 5 10 15
Lys Lys Thr Thr Val Arg Thr Pro Ser Trp Asn Val Asp Met Met Arg
20 25 30
Phe Asn Ile Asn Asp Phe Leu Pro Pro Gly Gly Gly Ser Asn Pro Leu
35 40 45
Thr Val Pro Phe Glu Tyr Tyr Arg Ile Arg Lys Val Lys Val Glu Phe
50 55 60
Trp Pro Cys Ser Pro Ile Thr Gln Asn Gly Arg Gly Val Gly Ser Thr
65 70 75 80
Ala Val Ile Leu Asp Ile Asn Phe Val Thr Lys Ala Asn Ala Leu Ile
85 90 95
Tyr Asp Pro Tyr Val Asn Tyr Ser Ser Arg His Thr Ile Thr Gln Pro
100 105 110
Phe Ser Tyr His Ser Arg Tyr Phe Thr Pro Lys Pro Val Leu Asp Arg
115 120 125
Thr Ile Asp Tyr Phe Gln Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu
130 135 140
Arg Leu Gln Thr Thr Gly Asn Val Asp His Val Gly Leu Gly Thr Ala
145 150 155 160
Phe Glu Asn Ser Ile Tyr Asp Gln Asp Tyr Asn Ile Arg Ile Thr Met
165 170 175
Tyr Val Gln Phe Arg Glu Phe Asn Leu Lys Asp Pro Pro Leu Asn Pro
180 185 190
Lys
<210> 3
<211> 552
<212> DNA
<213> porcine circovirus (porcine circovirus)
<400> 3
accatcggtt atactgtcaa gaaaaccaca gtcagaacgc cctcctggaa tgtggacatg 60
atgagattta atattaatga ttttcttccc ccaggagggg gctcaaaccc cctcactgtg 120
ccctttgaat actacagaat aaggaaggtt aaggttgaat tctggccctg ctccccaatc 180
acccagggtg acaggggagt gggctccact gctgttattc tagatgataa ctttgtaaca 240
aaggccaatg ccctaaccta tgacccctat gtaaactact cctcccgcca taccataacc 300
cagcccttct cctaccactc ccggtacttt accccgaaac ctgtcctgga tcggactatg 360
gattacttcc aacccaataa caaaagaaat caactctggc tgagactaca aactactgga 420
aatgtagacc atgtaggcct cggcactgcg ttcgaaaaca gtatatacga ccaggactac 480
aatatccgta taaccatgta tgtacaattc agagaattta atcttaaaga ccccccactt 540
aaccctaagt ga 552
Claims (10)
1. A porcine circovirus type 2 recombinant Cap protein has a sequence of sequence 2 in a sequence table.
2. The gene encoding the porcine circovirus type 2 recombinant Cap protein of claim 1.
3. The encoding gene of claim 2, wherein the sequence of the encoding gene is shown as sequence 1 in the sequence table.
4. The recombinant vector for expressing the porcine circovirus type 2 recombinant Cap protein of claim 1 is obtained by inserting the coding gene of the porcine circovirus type 2 recombinant Cap protein shown in the sequence 1 into an original vector.
5. The recombinant vector according to claim 4, wherein the starting vector is pET-30a (+).
6. The engineering bacteria for expressing the porcine circovirus type 2 recombinant Cap protein is characterized in that the engineering bacteria are recombinant bacteria for expressing porcine circovirus type 2 Cap recombinant protein virus particles obtained by introducing the recombinant vector of claim 4 or 5 into escherichia coli BL21(DE3) competence and screening.
7. The engineered bacterium expressing porcine circovirus type 2 recombinant Cap protein according to claim 6, wherein the engineered bacterium is Escherichia coli E.coli-PCV2-FJ-Cap, which is deposited at the China general microbiological culture Collection center at 7-16.2019 with the deposit number of CGMCC No. 18235.
8. A preparation method of porcine circovirus type 2 Cap recombinant protein virus particles comprises the following steps:
1) transforming the recombinant vector of claim 4 or 5 into escherichia coli BL21(DE3) competence to obtain a recombinant bacterium for expressing porcine circovirus type 2 Cap recombinant protein virions;
2) inducing and expressing the recombinant bacteria obtained in the step 1), collecting and crushing bacteria, and collecting inclusion bodies;
3) dissolving and renaturing the inclusion body obtained in the step 2) to obtain the assembled porcine circovirus type 2 Cap recombinant protein virions.
9. Use of the porcine circovirus type 2 recombinant Cap protein of claim 1 or the gene encoding the porcine circovirus type 2 recombinant Cap protein of claim 2 in the preparation of porcine circovirus type 2 recombinant Cap protein virions.
10. Use of the porcine circovirus type 2 recombinant Cap protein of claim 1 or the gene encoding the porcine circovirus type 2 recombinant Cap protein of claim 2 in the preparation of a vaccine for the prevention or treatment of porcine circovirus type 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911246097.3A CN110981945B (en) | 2019-12-08 | 2019-12-08 | Expression preparation and application of porcine circovirus type 2 recombinant Cap protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911246097.3A CN110981945B (en) | 2019-12-08 | 2019-12-08 | Expression preparation and application of porcine circovirus type 2 recombinant Cap protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110981945A CN110981945A (en) | 2020-04-10 |
| CN110981945B true CN110981945B (en) | 2021-10-19 |
Family
ID=70091188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911246097.3A Active CN110981945B (en) | 2019-12-08 | 2019-12-08 | Expression preparation and application of porcine circovirus type 2 recombinant Cap protein |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110981945B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114805501B (en) * | 2022-03-24 | 2024-06-25 | 中牧实业股份有限公司 | Porcine circovirus type 2 antigen composition and application thereof in antigen quantification method |
| CN114736310B (en) * | 2022-06-10 | 2022-10-28 | 北京华夏兴洋生物科技有限公司 | Protein and biological material for producing circovirus type 2 virus-like particles and application |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1311698A2 (en) * | 2000-05-03 | 2003-05-21 | University Of Guelph | Porcine adenovirus type 5 vector and vaccine |
| CN102296089B (en) * | 2011-04-20 | 2013-09-11 | 中国兽医药品监察所 | Method for efficiently preparing porcine circovirus 2 type empty capsid |
| WO2014113855A1 (en) * | 2013-01-25 | 2014-07-31 | Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig | Recombinant antigens of porcine circovirus 2 (pcv-2) for vaccine formulations, diagnostic kit and use thereof |
| CN103739717B (en) * | 2014-01-15 | 2015-07-22 | 北京市农林科学院 | Recombinant protein subunit vaccine for resisting porcine circovirus serotype 2 |
| CN104873966A (en) * | 2015-04-20 | 2015-09-02 | 浙江海隆生物科技有限公司 | Method for purifying porcine circovirus type 2 virus-like particles and preparation method of vaccine of porcine circovirus type 2 virus-like particles |
| CN105999255A (en) * | 2016-05-19 | 2016-10-12 | 华南农业大学 | Virus-like particle vaccine for PCV2 (porcine circovirus 2) as well as preparation method and application of virus-like particle vaccine |
| CN107034226A (en) * | 2017-03-17 | 2017-08-11 | 华南农业大学 | A kind of soluble recombinant protein and its expression and purification method and purposes |
| CN109609534A (en) * | 2018-12-26 | 2019-04-12 | 镇江瑞华生物科技有限公司 | A kind of method and its application using 3 type ORF2 albumen of Bacillus coli expression pig circular ring virus |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8834891B2 (en) * | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
| CN101948849A (en) * | 2010-09-02 | 2011-01-19 | 洛阳普莱柯生物工程有限公司 | Preparation and use of truncated Cap protein of porcine circovirus type 2 |
| CN102115755A (en) * | 2010-10-11 | 2011-07-06 | 洛阳普莱柯生物工程有限公司 | Pichia expression PCV2 (porcine circovirus 2) ORF2 (open reading frame 2) protein and subunit vaccine |
| CN103059142B (en) * | 2012-12-17 | 2015-02-25 | 重庆市畜牧科学院 | Recombinant protein of antigen to porcine circovirus and antigen to porcine reproductive and respiratory syndrome virus, and preparation method and application of recombinant protein |
| CN109125719B (en) * | 2017-06-19 | 2022-06-14 | 普莱柯生物工程股份有限公司 | Immunogenic composition containing porcine circovirus type 3 and porcine circovirus type 2 antigens and application thereof |
-
2019
- 2019-12-08 CN CN201911246097.3A patent/CN110981945B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1311698A2 (en) * | 2000-05-03 | 2003-05-21 | University Of Guelph | Porcine adenovirus type 5 vector and vaccine |
| CN102296089B (en) * | 2011-04-20 | 2013-09-11 | 中国兽医药品监察所 | Method for efficiently preparing porcine circovirus 2 type empty capsid |
| WO2014113855A1 (en) * | 2013-01-25 | 2014-07-31 | Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig | Recombinant antigens of porcine circovirus 2 (pcv-2) for vaccine formulations, diagnostic kit and use thereof |
| CN103739717B (en) * | 2014-01-15 | 2015-07-22 | 北京市农林科学院 | Recombinant protein subunit vaccine for resisting porcine circovirus serotype 2 |
| CN104873966A (en) * | 2015-04-20 | 2015-09-02 | 浙江海隆生物科技有限公司 | Method for purifying porcine circovirus type 2 virus-like particles and preparation method of vaccine of porcine circovirus type 2 virus-like particles |
| CN105999255A (en) * | 2016-05-19 | 2016-10-12 | 华南农业大学 | Virus-like particle vaccine for PCV2 (porcine circovirus 2) as well as preparation method and application of virus-like particle vaccine |
| CN107034226A (en) * | 2017-03-17 | 2017-08-11 | 华南农业大学 | A kind of soluble recombinant protein and its expression and purification method and purposes |
| CN109609534A (en) * | 2018-12-26 | 2019-04-12 | 镇江瑞华生物科技有限公司 | A kind of method and its application using 3 type ORF2 albumen of Bacillus coli expression pig circular ring virus |
Non-Patent Citations (3)
| Title |
|---|
| Characterization and potential use of truncated PCV2 capsid protein and its polyclonal antibody for diagnosis of PCV2 infections;Jiangbing Shuai等;《Acta Microbiologica Sinica》;20080104;第48卷(第1期);第85-90页 * |
| Immunogenicity and immunoprotection of porcine circovirus type 2 (PCV2) Cap protein displayed by Lactococcus lactis;Peng-chengLi等;《Vaccine》;20160127;第34卷(第5期);第696-702页 * |
| 猪圆环病毒2型ORF2基因的原核表达及反应原性分析;欧云文等;《动物医学进展》;20170420;第38卷(第4期);第1-6页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110981945A (en) | 2020-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112500458B (en) | Novel variant subunit vaccine of chicken infectious bursal disease virus, preparation method and application thereof | |
| CN106399138B (en) | Porcine circovirus type II oral virus-like particle vaccine and its preparation method and application | |
| CN112501186B (en) | Porcine circovirus 2 d-type CAP protein and application thereof in preparation of subunit vaccine | |
| CN110124025B (en) | Avian influenza and avian adenovirus type 4 bigeminal genetic engineering subunit vaccine and preparation method thereof | |
| CN107337718A (en) | A kind of gene for encoding carrying Cap gene of porcine circovirus type 2 and its application | |
| CN103255171B (en) | Recombinant virus-like particles of porcine circovirus 2 type codon optimized OFRF2 gene | |
| CN110423269B (en) | A recombinant porcine circovirus type 2 Cap protein with tandem dominant epitopes and its application | |
| CN107899008B (en) | Sick three subunit vaccines of a kind of pig epidemic diarrhea, transmissible gastroenteritis of swine, pig fourth type coronavirus | |
| CN105087624A (en) | Expression vector of Cap protein of porcine circovirus (PCV) 2 as well as construction method and application thereof | |
| CN112011556B (en) | Porcine circovirus 2b and 2d type bivalent virus-like particle vaccine as well as preparation method and application thereof | |
| CN110981945B (en) | Expression preparation and application of porcine circovirus type 2 recombinant Cap protein | |
| CN104693310B (en) | A kind of chimeric protein, virus-like particle and its application | |
| CN114058524A (en) | A Bursal subvirus particle vaccine and preparation method thereof | |
| CN103333849B (en) | Staphylococcus aureus mutant strain, and preparation method and applications thereof | |
| CN110680912A (en) | H3N2 and H3N8 subtype canine influenza bivalent inactivated vaccine as well as preparation method and application thereof | |
| CN109897832B (en) | Porcine circovirus type 3 virus strain and application thereof | |
| CN109694857B (en) | Recombinant baculovirus for expressing porcine circovirus 3Cap protein and application thereof | |
| CN108721615A (en) | A kind of method and its vaccine preparing duck tembusu virus inactivated vaccine | |
| CN100489092C (en) | Type II genetic marker strain of porcine circovirus and its application | |
| CN115960250A (en) | A kind of recombinant porcine circovirus type 3 trimeric protein and its preparation method and application | |
| CN109867713A (en) | A kind of canine distemper genetic engineering subunit vaccine | |
| CN113861277A (en) | Bovine rotavirus recombinant VP8 protein and application thereof | |
| CN111978411B (en) | Porcine reproductive and respiratory syndrome subunit vaccine and preparation method and application thereof | |
| CN102559606A (en) | A16 type strain of Coxsackie virus and application of the strain | |
| CN101979503B (en) | Production method of recombinant brucella expressing Asia I type foot-and-mouth disease virus VP1 gene and vaccine thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |